<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ:CMPS), a drug developer looking to accelerate patient access to psilocybin therapy for treatment-resistant depression. In recent days, Atai Life Sciences (Compass’ biggest shareholder) increased its ownership in Compass Pathways buying another 619,095 shares, taking its stake in the company from 19.4 to 20.8 percent.
...read full article on Benzinga
